The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; GlaxoSmithKline; Immunomedics; LEK; Novartis; Roche/Genentech; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech
 
Andrew Clamp
No Relationships to Disclose
 
Adrian David Cook
No Relationships to Disclose
 
Iain A. McNeish
Honoraria - AstraZeneca; Clovis Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene; Carrick Therapeutics; Clovis Oncology; Roche; Scancell Ltd.; Tesaro
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Olivier Colomban
No Relationships to Disclose